Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members
Open accessThe DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index; 19 of the 58 sources its claims cite were checked for support.
Abstract
We examined the role of hepatic heparan sulfate in triglyceride-rich lipoprotein metabolism by inactivating the biosynthetic gene GlcNAc N-deacetylase/N-sulfotransferase 1 (Ndst1) in hepatocytes using the Cre-loxP system, which resulted in an approximately 50% reduction in sulfation of liver heparan sulfate. Mice were viable and healthy, but they accumulated triglyceride-rich lipoprotein particles containing apoB-100, apoB-48, apoE, and apoCI-IV. Compounding the mutation with LDL receptor deficiency caused enhanced accumulation of both cholesterol- and triglyceride-rich particles compared with mice lacking only LDL receptors, suggesting that heparan sulfate participates in the clearance of cholesterol-rich lipoproteins as well. Mutant mice synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduction in hepatic VLDL uptake. Retinyl ester excursion studies revealed that clearance of intestinally derived lipoproteins also depended on hepatocyte heparan sulfate. These findings show that under normal physiological conditions, hepatic heparan sulfate proteoglycans play a crucial role in the clearance of both intestinally derived and hepatic lipoprotein particles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 22 Not checked · 102 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Total plasma cholesterol was not affected (80.1 ± 10.1 mg/dl versus 81.4 ± 9.1; n = 20; P = 0.68) (Figure 2B), which contrasts the phenotype of LDLR and LRP mutant mice (15,49).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Ndst1 f/f AlbCre + mice accumulate TRLs.
What the sources say
- Not checked — no full text of the sourcecites [15] Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695. source
- Supportedcites [49] Ishibashi, S., et al. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene deliv- ery. J. Clin. Invest. 92:883-893. source
The citation supports the contrast with LDLR-mutant mice, not the citing authors’ 80.1 versus 81.4 mg/dl result. In the Disrupted Allele Wildtype Allele section (Table I; page not provided), the source reports that LDLR-mutant mice have elevated total plasma cholesterol compared with wild-type littermates. (LLM, conf=0.90)
plainn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 2-O-sulfation of uronic acids (ΔUA2S-GlcNS and ΔUA2S-GlcNS6S) showed a larger decrease (15% in controls to 3% in the mutant), consistent with previous analyses of HS from mice containing systemic inactivation of Ndst1 (43,44).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Hepatocyte-specific Ndst1 gene disruption alters HS synthesis in liver.
What the sources say
- Supportedcites [43] Grobe, K., et al. 2005. Cerebral hypoplasia and cra- niofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development. 132:3777-3786. source
The citation supports the stated consistency with earlier Ndst1 analyses, not the citing study’s exact 15%-to-3% figures. The source’s Results and Table 1 report a marked decrease in 2-O-sulfated disaccharides in Ndst1 mutant embryos, from 9.7% in wild type to 3.8% in mutants. (LLM, conf=0.92)
- Partly supportedcites [44] Ledin, J., et al. 2004. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279:42732-42741. sourceExperimental — accuracy not yet measured
The Results (page unavailable; Table II and Fig. 6A) report that all species of 2-O-sulfated disaccharides decreased in NDST-1-deficient tissues, supporting the direction of the claim. The passages do not give the stated change from 15% in controls to 3% in the mutant, so that magnitude is not verified by our copy. (LLM, conf=0.83)
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Partly supportedcites [38] Mann, W.A., et al. 1995. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). J. Clin. Invest. 96:1100-1107. sourceExperimental — accuracy not yet measured
The Results report that apoE-1 (Lys146→Glu) bound heparin at 10% of the apoE-3 level, and the Abstract associates this mutant with type III hyperlipoproteinemia. The Discussion uses heparin as a model for cell-surface proteoglycans, but the paper does not directly show reduced HS binding or establish that several rare alleles cause severe hyperlipoproteinemia. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [39] Mann, W.A., et al. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associ- ated type III hyperlipoproteinemia. J. Lipid Res. 36:517-525. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [40] Lutz, E.P., et al. 2001. Heparin-binding defective lipoprotein lipase is unstable and causes abnor- malities in lipid delivery to tissues. J. Clin. Invest. 107:1183-1192. source
The Abstract reports that mice expressing LpL with reduced heparin binding had defective targeting of lipids to tissues, with decreased uptake in muscle and increased uptake in kidneys. The Discussion likewise reports altered tissue lipid uptake compared with mice expressing nonmutated LpL. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clearance of TRLs occurs normally in humans, WHHL rabbits, and mice deficient in LDLR (11)(12)(13).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [11] Rubinsztein, D.C., et al. 1990. Chylomicron rem- nant clearance from the plasma is normal in famil- ial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312. source
The Discussion (p. 1311) reports normal chylomicron-remnant clearance in human familial hypercholesterolemia subjects with varying degrees of LDL-receptor deficiency. In this three-citation sentence, that human finding is the part supported by this source; the rabbit and mouse findings are not attributed to it individually. (LLM, conf=0.92)
- Supportedcites [12] Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism geneti- cally distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:3623-3627. source
The indexed paper reports that LDL-receptor-deficient WHHL rabbits cleared chylomicrons from plasma at a normal rate, with radiolabeled components removed at comparable rates in WHHL and normal rabbits (section and page not supplied). This paper supports the WHHL-rabbit portion of the sentence; the human and mouse portions have separate citations. (LLM, conf=0.93)
- Partly supportedcites [13] Ishibashi, S., et al. 1996. Role of the low den- sity lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quan- titative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427. sourceExperimental — accuracy not yet measured
The Introduction reports little detectable remnant accumulation in LDLR-deficient humans and rabbits, and the Results report prompt clearance of injected remnants in LDLR-deficient mice. But the Results also show a fourfold larger retinyl-ester excursion in those mice after a fat load, so the unqualified claim of normal clearance in mice overstates the paper's findings. The passages supplied do not include page numbers. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
75 more claims · 4 with their cited sources checked
Create a free account to see all 139 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 39
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TRLs arising from LPL-mediated lipolysis are cleared by multiple hepatic receptors, including LDL receptor (LDLR), LDLR-related protein 1 (LRP1), and syndecan-1 (SDC), the predominant hepatic heparin sulfate proteoglycan (HSPG) (Bishop et al., 2008; Foley et al., 2013; MacArthur et al., 2007; Stanford et al., 2009).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as MacArthur et al., 2007
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that both Ldlr–/– and Sdc1–/– mice both accumulate plasma triglycerides”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954 -955).”
From Biological roles of glycans (2017) · cites this paper as [954]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, we showed previously that compounding Ldlr–/– with Ndst1f/fAlbCre+ mice causes an additive accumulation of plasma triglycerides and prolonged the delay in postprandial clearance manifested by each individual mutant (9).”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A modified uronic acid carbazole reaction
Bitter, T., & Muir, H. M. (1962) · Analytical Biochemistry · doi:10.1016/0003-2697(62)90095-7 · Cited by 6,274
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
An Automated Multidimensional Protein Identification Technology for Shotgun Proteomics
Wolters, D. A., Washburn, M. P., & Yates, J. R. (2001) · Analytical Chemistry · doi:10.1021/ac010617e · Cited by 1,819
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Self-citationIshibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Research works printed but not linked: 2
- Belting, M. 2003. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28:145-151. · DOI · Paper page
- Iverius, P., and Ostlund-Lindqvist, A. 1986. Prepa- ration, characterization, and measurement of lipo- protein lipase. In Methods in enzymology. J.J. Albers and J.P. Segrest, editors. Academic Press. Orlando, Florida, USA. 691-704.
Cited by
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“For example heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954, 955).”
BackgroundHeparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Self-citationSarrazin, S., Lamanna, W. C., & Esko, J. D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004952 · Cited by 1,516
“Altering the structure of HS by selective inactivation of sulfotransferases in hepatocytes led to the same phenotype and showed that the HS chains on syndecan-1 represent the binding site for the lipoproteins (MacArthur et al. 2007; Stanford et al. 2010).”
BackgroundSelf-citationTabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways
Goldberg, I. J., Eckel, R. H., & Abumrad, N. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800085-jlr200 · Cited by 362
“fect of proteoglycan sulfation associated with increased postprandial lipemia (8) is consistent with this type of lipoprotein uptake process.”
BackgroundTall, A. R. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01898.x · Cited by 436
Heparan Sulfate: Biosynthesis, Structure, and Function
(2016) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.02.009 · Cited by 298
“Capturing may result in endocytosis of a protein ligand, possibly along with bound HSPG (MacArthur et al., 2007) [Fig.”
BackgroundPalm, W., Sampaio, J. L., Brankatschk, M., Carvalho, M., Mahmoud, A., Shevchenko, A., & Eaton, S. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002828 · Cited by 287
“Similarly, the role of heparan sulfate proteoglycans as endocytic lipoprotein receptors is conserved between mammals and flies [20,21].”
BackgroundChapter 3 Interactions Between Heparan Sulfate and Proteins—Design and Functional Implications
(2009) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(09)76003-4 · Cited by 274
“Capturing may result in endocytosis of a protein ligand, possibly along with boundHSPG (MacArthur et al., 2007; Spijkers et al., 2008) (Fig.”
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274
Self-citationRecent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
Varbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
“However, hepatic uptake of remnants is complex and not fully understood, andmechanisms other than uptake via the LDL and LRP receptors have been proposed, such as internalization after binding to heparan sulfate proteoglycans (MacArthur et al., 2007).”
BackgroundTriglyceride lpases and atherosclerosis
Olivecrona, G., & Olivecrona, T. (1995) · Current Opinion in Lipidology · doi:10.1097/00041433-199510000-00009 · Cited by 238
Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
Self-citationKidambi, S., Yarmush, R. S., Novik, E., Chao, P., Yarmush, M. L., & Nahmias, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906820106 · Cited by 213
“be involved the transport and metabolism of several hydrophobic drugs (27, 28).”
BackgroundThe regulation of ApoB metabolism by insulin
Haas, M. E., Attie, A. D., & Biddinger, S. B. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.04.001 · Cited by 187
The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight
Dallinga-Thie, G. M., Franssen, R., Mooij, H. L., Visser, M. E., Hassing, H. C., Peelman, F., Kastelein, J. J. P., Péterfy, M., & Nieuwdorp, M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.027 · Cited by 181
“GPIHBP1, A Novel Protein Involved in Triglyceride Lipolysis When mature active LPL is secreted to the parenchymal cell surface it will bind to HSPGs.”
BackgroundInfluentialPathophysiology of heparan sulphate: many diseases, few drugs
Lindahl, U., & Kjellén, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12061 · Cited by 189
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
The Recovery Time Course of the Endothelial Cell Glycocalyx In Vivo and Its Implications In Vitro
Potter, D. R., Jiang, J., & Damiano, E. R. (2009) · Circulation Research · doi:10.1161/circresaha.108.191585 · Cited by 176
Targeting heparin and heparan sulfate protein interactions
Weiss, R. J., Esko, J. D., & Tor, Y. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01058c · Cited by 172
Self-citationMolecular processes that handle — and mishandle — dietary lipids
Williams, K. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35206 · Cited by 160
Felmlee, D., Hafirassou, M., Lefevre, M., Baumert, T., & Schuster, C. (2013) · Viruses · doi:10.3390/v5051292 · Cited by 158
“Liver specific inactivation in mice of enzymes that regulate the degree of sulfation of proteoglycans on hepatocyte surfaces resulted in an accumulation of remnants over and above LDLr inactivation alone [138–140].”
BackgroundEzetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome
Deushi, M., Nomura, M., Kawakami, A., Haraguchi, M., Ito, M., Okazaki, M., Ishii, H., & Yoshida, M. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.023 · Cited by 163
“but not secretion of triglyceride [30].”
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159
Clearance mechanisms of von Willebrand factor and factor VIII
Lenting, P. J., van Schooten, C. J. M., & Denis, C. V. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02572.x · Cited by 153
Charlton, M., Viker, K., Krishnan, A., Sanderson, S., Veldt, B., Kaalsbeek, A. J., Kendrick, M., Thompson, G., Que, F., Swain, J., et al. (2009) · Hepatology · doi:10.1002/hep.22927 · Cited by 150
Heparan Sulphate Biosynthesis and Disease
Nadanaka, S., & Kitagawa, H. (2008) · The Journal of Biochemistry · doi:10.1093/jb/mvn040 · Cited by 132
Sugaya, N., Habuchi, H., Nagai, N., Ashikari‐Hada, S., & Kimata, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705948200 · Cited by 133
Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A., & Baker, A. H. (2010) · Viruses · doi:10.3390/v2102290 · Cited by 120
Heparan sulfate proteoglycans at a glance
Kirkpatrick, C. A., & Selleck, S. B. (2007) · Journal of Cell Science · doi:10.1242/jcs.03432 · Cited by 136
“It has been known for some time that endocytosis of low density lipoprotein (LDL) by the LDL-receptor-related protein (LRP) requires HSPGs (Mahley and Ji, 1999), but recent work has shown that HSPGs independently mediate uptake of triglyceride-rich lipoproteins in the liver ( MacArthur et al., 2007 ).”
BackgroundSyndecan-1 Is Required to Maintain Intradermal Fat and Prevent Cold Stress
Kasza, I., Suh, Y., Wollny, D., Clark, R. J., Roopra, A., Colman, R. J., MacDougald, O. A., Shedd, T. A., Nelson, D. W., Yen, M.-I., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004514 · Cited by 107
“Specifically, Esko and colleagues observed that Sdc1 was required for the uptake of VLDL particles by liver [19,49].”
BackgroundBassendine, M. F., Sheridan, D. A., Bridge, S. H., Felmlee, D. J., & Neely, R. D. G. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0356-2 · Cited by 124
“The process involves an initial binding of TRL via apoE to HSPG [175] or SRBI [176] before subsequent LDLr internalization via apoE and apoB.”
BackgroundLaatsch, A., Merkel, M., Talmud, P. J., Grewal, T., Beisiegel†, U., & Heeren, J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.046 · Cited by 111
“[4] MacArthur JM, Bishop JR, Stanford KI, et al.”
BackgroundScarpellini, A., Germack, R., Lortat‐Jacob, H., Muramatsu, T., Billett, E. E., Johnson, T. S., & Verderio, E. A. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012948 · Cited by 115
Lipolysis Stimulated Lipoprotein Receptor
Yen, F. T., Roitel, O., Bonnard, L., Notet, V., Pratte, D., Stenger, C., Magueur, E., & Bihain, B. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801027200 · Cited by 93
Lefèvre, M., Felmlee, D. J., Parnot, M., Baumert, T. F., & Schuster, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095550 · Cited by 111
“Moreover, SDC1 is the primary proteoglycan receptor mediating binding, uptake, and degradation of VLDL both in vitro [14] and in vivo [15,16].”
Recent insights into factors affecting remnant lipoprotein uptake
Williams, K. J., & Chen, K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338cabc · Cited by 91
Hyperlipoproteinemia Type 3: The Forgotten Phenotype
Hopkins, P. N., Brinton, E. A., & Nanjee, M. N. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0440-2 · Cited by 93
Lipoproteins and their receptors in embryonic development: more than cholesterol clearance
Willnow, T. E., Hammes, A., & Eaton, S. (2007) · Development · doi:10.1242/dev.004408 · Cited by 95
“Finally, heparan sulfate proteoglycans can also bind and internalize lipoproteins independently of LRPs (MacArthur et al., 2007; Wilsie et al., 2006) and clearly have important and ubiquitous functions in regulating the spread of Wnt and Hh family proteins (Blair, 2005; Hacker et al., 2005;…”
BackgroundInfluentialAltered Heparan Sulfate Structure in Mice with Deleted NDST3 Gene Function
Pallerla, S. R., Lawrence, R., Lewejohann, L., Pan, Y., Fischer, T., Schlomann, U., Zhang, X., Esko, J. D., & Grobe, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709774200 · Cited by 81
Self-citationSheng, J., Liu, R., Xu, Y., & Liu, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.224311 · Cited by 88
Glycan Antagonists and Inhibitors: A Fount for Drug Discovery
Brown, J. R., Crawford, B. E., & Esko, J. D. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701751611 · Cited by 99
“However, mutations induced in specific tissues or in adult animals do not cause lethality or gross dysfunction, suggesting that small changes in HS structure can be tolerated (Fuster et al., 2007; MacArthur et al., 2007).”
BackgroundSelf-citationHeparan Sulfate 2-O-Sulfotransferase Is Required for Triglyceride-rich Lipoprotein Clearance
Stanford, K. I., Wang, L., Castagnola, J., Song, D., Bishop, J. R., Brown, J. R., Lawrence, R., Bai, X., Habuchi, H., Tanaka, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.063701 · Cited by 84
Self-citationGordts, P. L. S. M., Foley, E. M., Lawrence, R., Sinha, R., Lameda-Diaz, C., Deng, L., Nock, R., Glass, C. K., Erbilgin, A., Lusis, A. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.016 · Cited by 86
“However, inactivation of Ndst1 in macrophages induced relatively modest changes in overall HS composition compared to other cell types (Figure S1) (MacArthur et al., 2007), decreasing the level of N-sulfation from 53 N-sulfoglucosamine residues/100 disaccharides in wild-type macrophages to 44/100 disaccharides in the…”
BackgroundMethodInfluentialSelf-citationA Systems View of the Heparan Sulfate Interactome
Toledo, A. G., Sorrentino, J. T., Sandoval, D. R., Malmström, J. A., Lewis, N. E., & Esko, J. D. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420988661 · Cited by 90
Self-citationApolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans
Gonzales, J. C., Gordts, P. L. S. M., Foley, E. M., & Esko, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67398 · Cited by 79
“We previously did not observe ApoAV in TRLs accumulating in Ndst1f/fAlbCre+ mice (12), presumably because of a lack of sensitivity of the staining techniques.”
InfluentialSelf-citationBradshaw, A. C., Parker, A. L., Duffy, M. R., Coughlan, L., van Rooijen, N., Kähäri, V., Nicklin, S. A., & Baker, A. H. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001142 · Cited by 84
“Interestingly, liver HS have been shown to possess a specialised structure, with much higher levels of N - and O -sulfation than HS from other tissues [31,32,33].”
Shen, J., Tong, X., Sud, N., Khound, R., Song, Y., Maldonado-Gomez, M. X., Walter, J., & Su, Q. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307597 · Cited by 81
Foley, E. M., Gordts, P. L. S. M., Stanford, K. I., Gonzales, J. C., Lawrence, R., Stoddard, N., & Esko, J. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301637 · Cited by 77
“Recently, we showed that Cre-mediated inactivation of Ndst1 or uronyl 2-O-sulfotransferase (Hs2st) in hepatocytes results in the accumulation of fasting triglycerides and delayed clearance of intestinally derived lipoproteins because of undersulfation of heparan sulfate.(15,28) In subsequent studies, we identified syn…”
BackgroundResultSelf-citationADAMTS‐5: A difficult teenager turning 20
Santamaria, S. (2020) · International Journal of Experimental Pathology · doi:10.1111/iep.12344 · Cited by 78
Glycosaminoglycan remodeling during diabetes and the role of dietary factors in their modulation
Gowd, V., Gurukar, A., & Chilkunda, N. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i4.67 · Cited by 74
Retinyl ester hydrolases and their roles in vitamin A homeostasis
Schreiber, R., Taschler, U., Preiss-Landl, K., Wongsiriroj, N., Zimmermann, R., & Lass, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.05.001 · Cited by 70
Pathophysiology of hypertriglyceridemia
Hassing, H. C., Surendran, R. P., Mooij, H. L., Stroes, E. S. G., Nieuwdorp, M., & Dallinga‐Thie, G. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.11.010 · Cited by 85
“Mice lacking Ndst1 have a 50% reduction of hepatic HSPG sulfation [47].”
BackgroundA role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation
Frederick, J. P., Tafari, A. T., Wu, S.-M., Megosh, L. C., Chiou, S.-T., Irving, R. P., & York, J. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801182105 · Cited by 67
“essentially as described (55) with modifications as detailed in SI Text.”
MethodAbnormal Patterns of Lipoprotein Lipase Release into the Plasma in GPIHBP1-deficient Mice
Weinstein, M. M., Yin, L., Beigneux, A. P., Davies, B. S. J., Gin, P., Estrada, K., Melford, K., Bishop, J. R., Esko, J. D., Dallinga-Thie, G. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806067200 · Cited by 67
Self-citationLaatsch, A., Panteli, M., Sornsakrin, M., Hoffzimmer, B., Grewal, T., & Heeren, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029385 · Cited by 65
“The role of lipoprotein receptors in TRL uptake and endosomal trafficking of TRL-derived apoE has been investigated in several studies [6,7,11,12,14,16,23].”
BackgroundAl‐Sharea, A., Murphy, A. J., Huggins, L. A., Hu, Y., Goldberg, I. J., & Nagareddy, P. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.02.028 · Cited by 67
“This defect in TG rich lipoprotein clearance was attributed by us and others to impaired heparan sulfate proteoglycans (HSPG) in the liver [20, 29, 30].”
BackgroundTetrasulfated Disaccharide Unit in Heparan Sulfate
Mochizuki, H., Yoshida, K., Shibata, Y., & Kimata, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801586200 · Cited by 73
Glycosaminoglycan-driven lipoprotein uptake protects tumours from ferroptosis
Calhoon, D., Sang, L., Ji, F., Bezwada, D., Hsu, S., Cai, F., Kim, N., Basu, A., Wu, R., Pimentel, A., et al. (2025) · Nature · doi:10.1038/s41586-025-09162-0 · Cited by 80
Li, L., Thompson, P. A., & Kitchens, R. L. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800172-jlr200 · Cited by 64
Amadi, B., Fagbemi, A. O., Kelly, P. M., Mwiya, M., Torrente, F., Salvestrini, C., Day, R. M., Golden, M. H., Eklund, E. A., Freeze, H. H., et al. (2008) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27092 · Cited by 63
“Fatty liver, caused by low hepatic lipoprotein lipase expression and high serum free fatty acids (34), is explicable on the basis that hepatic lipoprotein lipase localization and fatty acid uptake are HSPG dependent (35, 36).”
BackgroundHe, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
“…genes participate in lipid metabolism through various mechanisms, such as facilitating the function of lipid uptake receptors ( ADAM17 [59], HS3ST5 [60, 61]), impacting lipogenesis via adjusting substrate availability ( BCKDK [62]), and altering lipogenesis signaling pathways ( FERMT2 [63],…”
Triglyceride lipases and atherosclerosis
Olivecrona, G., & Olivecrona, T. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ded83 · Cited by 70
History of Discovery: Platelet-Derived Growth Factor
Bowen‐Pope, D. F., & Raines, E. W. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179556 · Cited by 69
Ehrhardt, N., Doche, M. E., Chen, S., Mao, H. Z., Walsh, M. T., Bedoya, C., Guindi, M., Xiong, W., Ignatius Irudayam, J., Iqbal, J., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx159 · Cited by 60
ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m093740 · Cited by 59
“Ndst1Alb-Cre, ApoeNdst1Alb-Cre, and LdlrNdst1Alb-Cre mice were generated and genotyped as described (26, 27).”
Self-citationBishop, J. R., Passos‐Bueno, M. R., Fong, L. G., Stanford, K. I., Gonzales, J. C., Yeh, E., Young, S. G., Bensadoun, A., Witztum, J. L., Esko, J. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013919 · Cited by 59
“Note that mutants lacking the transmembrane heparan sulfate proteoglycan, syndecan 1, or hepatocyte sulfotransferases involved in heparan sulfate assembly develop hypertriglyceridemia due to defects in hepatic clearance of remnant particles [24,25,26].”
BackgroundMethodSelf-citationChen, K., Liu, M.-L., Schaffer, L., Li, M., Boden, G., Wu, X., & Williams, K. J. (2010) · Hepatology · doi:10.1002/hep.23916 · Cited by 56
Triglyceride-Rich Lipoproteins and Plasma Lipid Transport
Havel, R. J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.178756 · Cited by 57
Metabolic and Signaling Functions of Cancer Cell-Derived Extracellular Vesicles
Fonseca, P., Vardaki, I., Occhionero, A., & Panaretakis, T. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.04.004 · Cited by 60
Inhibition of hepatic sulfatase-2 In Vivo : A novel strategy to correct diabetic dyslipidemia
Hassing, C. H., Mooij, H., Guo, S., Monia, B. P., Chen, K., Kulik, W., Dallinga-Thie, G. M., Nieuwdorp, M., Stroes, E. S. G., & Williams, K. J. (2012) · Hepatology · doi:10.1002/hep.25580 · Cited by 49
Koska, J., Yassine, H., Trenchevska, O., Sinari, S., Schwenke, D. C., Yen, F. T., Billheimer, D., Nelson, R. W., Nedelkov, D., & Reaven, P. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p064816 · Cited by 55
“These additional pathways include the LDL-receptor (44), LDL receptor-related protein 1 (45) and heparan sulfate proteoglycans (46, 47).”
Human genetic disorders and knockout mice deficient in glycosaminoglycan
Mizumoto, S., Yamada, S., & Sugahara, K. (2014) · BioMed Research International · doi:10.1155/2014/495764 · Cited by 54
“Ndst1 conditional knockout mice specific for the liver accumulated triglyceride-rich lipoproteins due to a reduction in the clearance of cholesterol-rich lipoprotein particles [148, 163].”
BackgroundMethodYamauchi, Y., Deguchi, N., Takagi, C., Tanaka, M., Dhanasekaran, P., Nakano, M., Handa, T., Phillips, M. C., Lund-Katz, S., & Saito, H. (2008) · Biochemistry · doi:10.1021/bi8003999 · Cited by 53
“The various anti-atherogenic functions of apoE, such as facilitated remnant lipoprotein uptake by the liver (8,50) and cholesterol efflux from macrophages (16,17), are achieved through its interaction with cell-surface GAG.”
BackgroundThe heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
Gordts, P. L. S. M., & Esko, J. D. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.05.010 · Cited by 54
“NDST1 inactivation reduced overall HS sulfation on hepatocytes by 50% due to coupling of the biosynthetic reactions (including 2-O- and 6-O-sulfation), rendering the normally highly sulfated liver HSPGs incapable of binding apolipoproteins exposed on the TRLs [54, 57, 58].”
BackgroundSelf-citationComplexity of microRNA function and the role of isomiRs in lipid homeostasis
Vickers, K. C., Sethupathy, P., Baran‐Gale, J., & Remaley, A. T. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r034801 · Cited by 59
Apolipoprotein C3: form begets function
Bornfeldt, K. E. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 45
“Thus, hepatic heparan sulfate is a critical part of the mechanism of clearing both cholesterol-rich lipoprotein particles and triglyceride-containing lipoprotein particles, and this effect is accentuated in states in which LDL receptors are downregulated (55).”
BackgroundToth, P. P., Hamon, S. C., Jones, S. R., Martin, S. S., Joshi, P. H., Kulkarni, K. R., Banerjee, P., Hanotin, C., Roth, E. M., & McKenney, J. M. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0197-4 · Cited by 50
Tamaru, M., Akita, H., Kajimoto, K., Sato, Y., Hatakeyama, H., & Harashima, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.02.016 · Cited by 48
Hu, L., van der Hoogt, C. C., Espirito Santo, S. M. S., Out, R., Kypreos, K. E., van Vlijmen, B. J. M., Van Berkel, T. J. C., Romijn, J. A., Havekes, L. M., van Dijk, K. W., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800130-jlr200 · Cited by 49
Hepatic Heparan Sulfate Proteoglycans and Endocytic Clearance of Triglyceride-Rich Lipoproteins
Foley, E. M., & Esko, J. D. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)93010-x · Cited by 54
“Liver HS is especially rich in N- and 2-O-sulfation, modifications that are required for lipoprotein binding and uptake.(47,48) The degree of substitution of the core protein could also be a variable.”
BackgroundSelf-citationShedding of Syndecan–1 From Human Hepatocytes Alters Very Low Density Lipoprotein Clearance
Deng, Y., Foley, E. M., Gonzales, J. C., Gordts, P. L. S. M., Li, Y., & Esko, J. D. (2011) · Hepatology · doi:10.1002/hep.24626 · Cited by 48
“Genetic studies in which heparan sulfate assembly was selectively altered in mouse hepatocytes by Cre-loxP targeting of two sulfotransferases demonstrated the importance of the heparan sulfate chains in hepatic TRL clearance.(9,10) Furthermore, direct genetic evidence has been provided showing that syndecan-1 is the p…”
BackgroundSelf-citationDou, W., Xu, Y., Pagadala, V., Pedersen, L. C., & Liu, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664409 · Cited by 46
“Conditional knock-out of NDST-1 uncovered a series of physiological and pathological roles, including lipoprotein clearance (14), development of lobuloalveolar of mammary gland (15), neutrophil trafficking (16), and inhibition of tumor angiogenesis (17).”
BackgroundmicroRNA‐379 couples glucocorticoid hormones to dysfunctional lipid homeostasis
de Guia, R. M., Rose, A. J., Sommerfeld, A., Seibert, O., Strzoda, D., Zota, A., Feuchter, Y., Krones, A., Sijmonsma, T., Kirilov, M., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201490464 · Cited by 48
“Mechanistically, TRL clearance works in several steps involving the action of LDLR, LRP (LDLR-related protein), LSR, VLDLR, and HSPGs (heparan sulfate proteoglycans) (MacArthur et al, 2007).”
BackgroundNischalke, H. D., Lutz, P., Krämer, B., Söhne, J., Müller, T., Rosendahl, J., Fischer, J., Berg, T., Hittatiya, K., Fischer, H.-P., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.06.006 · Cited by 46
“Interaction between proteoglycans and lipid metabolism has been shown before: mice with diminished sulfation of hepatic heparan sulfates display increased levels of triglyceride-rich lipoproteins [38].”
BackgroundA new, powerful player in lipoprotein metabolism: brown adipose tissue
Bartelt, A., Merkel, M., & Heeren, J. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0858-3 · Cited by 52
Goldberg, I. J., Hu, Y., Noh, H. L., Wei, J. C., Huggins, L. A., Rackmill, M. G., Hamai, H., Reid, B. N., Blaner, W. S., & Huang, L. (2008) · Diabetes · doi:10.2337/db08-0083 · Cited by 52
“Recently, liver-specific deletion of Ndst1, which is responsible for proteoglycan sulfation, led to hyperlipidemia, a process that was augmented when LDL receptors were deficient (34).”
BackgroundHassing, H. C., Surendran, R. P., Derudas, B., Verrijken, A., Francque, S. M., Mooij, H. L., Bernelot Moens, S. J., Hart, L. M. '., Nijpels, G., Dekker, J. M., et al. (2014) · Obesity · doi:10.1002/oby.20682 · Cited by 40
“During the past decades, hepatic heparan sulfate proteoglycans (HSPGs) (13-16) and in particular the syndecan-1 HSPG, have been implicated in TRL”
BackgroundMinahk, C. J., Kim, K.-W., Nelson, R. C., Trigatti, B. L., Lehner, R. S., & Vance, D. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706995200 · Cited by 45
Dagälv, A., Holmborn, K., Kjellén, L., & Åbrink, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303891 · Cited by 42
Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans
Mooij, H. L., Moens, S. J. B., Gordts, P. L. S. M., Stanford, K., Foley, E. M., van den Boogert, M. W., Witjes, J. J., Hassing, H. C., Tanck, M. W. T., van de Sande, M. A. J., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m053504 · Cited by 41
Self-citationStenger, C., Hanse, M., Pratte, D., Mbala, M., Akbar, S., Koziel, V., Escanyé, M., Kriem, B., Malaplate, C., Olivier, J. L., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-160440 · Cited by 44
“a significant increase in postprandial lipemia (10).”
Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management
Faria‐Ramos, I., Poças, J., Marques, C., Santos‐Antunes, J., Macedo, G., Reis, C. A., & Magalhães, A. (2021) · Biomolecules · doi:10.3390/biom11020136 · Cited by 43
“HSPGs are also important modulators of metabolism, as illustrated by their role in the liver mediated clearance of triglyceride-rich lipoproteins [57].”
BackgroundMice Deficient in Heparan Sulfate N-Deacetylase/N-Sulfotransferase 1
Ringvall, M., & Kjellén, L. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)93003-2 · Cited by 44
“A reduction of the clearance of intestinally derived and hepatic lipoprotein particles was observed in Ndst1f/fAlbCreþ mice, where liver HS sulfation was reduced to about 50%.(87) In later publications, it was demonstrated that syndecan-1 was responsible for the HS mediated uptake and that in addition to N-sulfate gro…”
Thornalley, P. J., & Rabbani, N. (2011) · Free Radical Research · doi:10.3109/10715762.2010.534162 · Cited by 37
“LDL binds to proteoglycans (PGs) in hepatocytes and fi broblasts which is now thought to be part of the cellular uptake mechanism of triglyceride-rich lipoprotein particles [96,97].”
BackgroundKegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Self-citationIzvolsky, K. I., Lü, J., Martin, G. S., Albrecht, K. H., & Cardoso, W. V. (2008) · genesis · doi:10.1002/dvg.20355 · Cited by 38
“During adult life Hs6st1 is expressed at high level in the liver, and there is recent evidence implicating liver heparan sulfates in lipoprotein metabolism (MacArthur et al., 2007).”
BackgroundMatikainen, N., Burza, M. A., Romeo, S., Hakkarainen, A., Adiels, M., Folkersen, L., Eriksson, P., Lundbom, N., Ehrenborg, E., Orho-Melander, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079473 · Cited by 31
“The importance of the syndecan-1 HSPG pathway for hepatic clearance of TRLs in mice has been demonstrated by systemic deletion of syndecan-1 and hepatocyte-specific inactivation of sulfotransferases involved in HSPG biosynthesis [16,29,30].”
Background
Metadata
- Authors
- MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D.
- Affiliations
- University of California San Diego (US)
- Cornell University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-01-02
- Volume
- 117
- Issue
- 1
- Pages
- 153-164
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1716206
- OpenAlex
- W2157280645
- Cited by
- 216
- References
- 91
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 14 · 2015: 12 · 2014: 17 · 2013: 14 · 2012: 11
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institutes of Health (HL57345, GM33063)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (HL 57345, P50HL056989, P01HL057345, HL-56989)
- National Institute of General Medical Sciences (R01GM033063, R37GM033063, GM-33063)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- heparan sulfate proteoglycans, triglyceride-rich lipoproteins, lipoprotein clearance, NDST1, LDL receptor, hepatic lipoprotein metabolism, apolipoproteins
- MeSH terms
- Apolipoproteins E, Humans, Lipoproteins, Liver, Receptors, LDL, Triglycerides, Hypertriglyceridemia, Fibroblast Growth Factor 2, Heparan Sulfate Proteoglycans, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.